The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

Dpyd  -  dihydropyrimidine dehydrogenase

Rattus norvegicus

Synonyms: DHPDHase, DPD, Dihydrothymine dehydrogenase, Dihydrouracil dehydrogenase
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Dpyd

  • These results suggested that DPD activity and protein level were maintained and that 5-FU pharmacokinetics was not altered in the presence of liver damage accompanied by a significant reduction in CYP2B activity and protein level, supporting previous clinical studies showing that mild to moderate liver dysfunction does not affect 5-FU disposition [1].
  • Protein depletion results in increased toxicity to 5-FU, which is associated with a significantly decreased rate of hepatic metabolism and clearance of 5-FU and a significant decrease in hepatic DPD activity [2].

High impact information on Dpyd


Biological context of Dpyd


Anatomical context of Dpyd


Associations of Dpyd with chemical compounds


Other interactions of Dpyd


Analytical, diagnostic and therapeutic context of Dpyd


  1. Dihydropyrimidine dehydrogenase activity and fluorouracil pharmacokinetics with liver damage induced by bile duct ligation in rats. Tateishi, T., Watanabe, M., Nakura, H., Tanaka, M., Kumai, T., Sakata, S.F., Tamaki, N., Ogura, K., Nishiyama, T., Watabe, T., Kobayashi, S. Drug Metab. Dispos. (1999) [Pubmed]
  2. The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism. Davis, L.E., Lenkinski, R.E., Shinkwin, M.A., Kressel, H.Y., Daly, J.M. Cancer (1993) [Pubmed]
  3. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cao, S., Baccanari, D.P., Joyner, S.S., Davis, S.T., Rustum, Y.M., Spector, T. Cancer Res. (1995) [Pubmed]
  4. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cao, S., Rustum, Y.M., Spector, T. Cancer Res. (1994) [Pubmed]
  5. Relationship between circadian-dependent toxicity of 5-fluorodeoxyuridine and circadian rhythms of pyrimidine enzymes: possible relevance to fluoropyrimidine chemotherapy. Zhang, R., Lu, Z., Liu, T., Soong, S.J., Diasio, R.B. Cancer Res. (1993) [Pubmed]
  6. Effects of uridine and thymidine on the degradation of 5-fluorouracil, uracil, and thymine by rat liver dihydropyrimidine dehydrogenase. Tuchman, M., Ramnaraine, M.L., O'Dea, R.F. Cancer Res. (1985) [Pubmed]
  7. Cloning of rat dihydropyrimidine dehydrogenase and correlation of its mRNA increase in the rat liver with age. Kimura, M., Sakata, S.F., Matoba, Y., Matsuda, K., Kontani, Y., Kaneko, M., Tamaki, N. J. Nutr. Sci. Vitaminol. (1998) [Pubmed]
  8. Synthesis and antiviral activity of novel anti-VZV 5-substituted uracil nucleosides with a cyclopropane sugar moiety. Onishi, T., Mukai, C., Nakagawa, R., Sekiyama, T., Aoki, M., Suzuki, K., Nakazawa, H., Ono, N., Ohmura, Y., Iwayama, S., Okunishi, M., Tsuji, T. J. Med. Chem. (2000) [Pubmed]
  9. Circadian rhythm of rat liver dihydropyrimidine dehydrogenase. Possible relevance to fluoropyrimidine chemotherapy. Harris, B.E., Song, R.L., He, Y.J., Soong, S.J., Diasio, R.B. Biochem. Pharmacol. (1988) [Pubmed]
  10. (R)-5-fluoro-5,6-dihydrouracil: kinetics of oxidation by dihydropyrimidine dehydrogenase and hydrolysis by dihydropyrimidine aminohydrolase. Porter, D.J., Harrington, J.A., Almond, M.R., Lowen, G.T., Spector, T. Biochem. Pharmacol. (1994) [Pubmed]
  11. A possible mechanism of eighteen patient deaths caused by interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Okuda, H., Ogura, K., Kato, A., Takubo, H., Watabe, T. J. Pharmacol. Exp. Ther. (1998) [Pubmed]
  12. Subcellular localization of dihydropyrimidine dehydrogenase. Van Kuilenburg, A.B., Van Lenthe, H., Wanders, R.J., Van Gennip, A.H. Biol. Chem. (1997) [Pubmed]
  13. Supplemented gamma-linolenic acid and eicosapentaenoic acid influence bone status in young male rats: effects on free urinary collagen crosslinks, total urinary hydroxyproline, and bone calcium content. Claassen, N., Potgieter, H.C., Seppa, M., Vermaak, W.J., Coetzer, H., Van Papendorp, D.H., Kruger, M.C. Bone (1995) [Pubmed]
  14. Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model. Cao, S., Lu, K., Tóth, K., Slocum, H.K., Shirasaka, T., Rustum, Y.M. Clin. Cancer Res. (1999) [Pubmed]
  15. In vitro and in vivo disposition and metabolism of 3'-deoxy-2',3'-didehydrothymidine. Cretton, E.M., Zhou, Z., Kidd, L.B., McClure, H.M., Kaul, S., Hitchcock, M.J., Sommadossi, J.P. Antimicrob. Agents Chemother. (1993) [Pubmed]
  16. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels. Jiang, H., Lu, J., Ji, J. Br. J. Pharmacol. (2004) [Pubmed]
  17. Pyrimidine catabolism: individual characterization of the three sequential enzymes with a new assay. Traut, T.W., Loechel, S. Biochemistry (1984) [Pubmed]
  18. 5-ethynyl-2(1H)-pyrimidinone: aldehyde oxidase-activation to 5-ethynyluracil, a mechanism-based inactivator of dihydropyrimidine dehydrogenase. Porter, D.J., Harrington, J.A., Almond, M.R., Lowen, G.T., Zimmerman, T.P., Spector, T. Biochem. Pharmacol. (1994) [Pubmed]
  19. The activity of dihydropyrimidine dehydrogenase from rat liver was not affected by any of five 5-hydroxytryptamine antagonists. Tateishi, T., Nakura, H., Watanabe, M., Tanaka, M., Kumai, T., Kobayashi, S. Cancer Lett. (1996) [Pubmed]
  20. Interleukin-2 as a modulator of 5-fluorouracil in hepatic arterial immunochemotherapy for liver metastases. Okuno, K., Hirai, N., Takemoto, Y., Kawai, I., Yasutomi, M. Hepatogastroenterology (2000) [Pubmed]
  21. Parenteral nutrition decreases hepatic dihydropyrimidine dehydrogenase activity and modulates catabolism of 5-fluorouracil in rats. Taniguchi, M., Yano, M., Tsujinaka, T., Ogawa, A., Morita, S., Kaneko, K., Akiyama, Y., Miki, H., Monden, M. In Vivo (2003) [Pubmed]
WikiGenes - Universities